Ligand validation:8QLA

IBL: Azo-Combretastatin A4 (cis)

IBL is a Ligand Of Interest in 8QLA designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
8QLA_IBL_B_502	5%	58%	0.209	0.611	0.45	1.13	-	4	1	0	100%	0.2
8QL2_IBL_B_501	76%	52%	0.066	0.9	0.52	1.33	-	4	0	0	100%	1
8QEA_IBL_B_702	50%	28%	0.081	0.83	1.63	1.29	5	4	1	0	100%	1
8QL4_IBL_B_702	44%	40%	0.097	0.822	1.22	1.13	2	2	0	0	100%	1
8QL3_IBL_B_702	40%	23%	0.088	0.795	1.65	1.55	7	8	1	0	100%	1
8QL9_IBL_B_502	13%	58%	0.15	0.686	0.45	1.13	-	4	1	0	100%	0.5
8QL5_IBL_B_702	12%	40%	0.128	0.649	1.22	1.13	2	2	0	0	100%	0.59

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.